key: cord-0901600-5qt588r5 authors: Wang, J. G.; Liu, B.; Percha, B.; Pan, S.; Goel, N.; Mathews, K.; Gao, C.; Tandon, P.; Tomlinson, M.; Yoo, E.; Howell, D.; Eisenberg, E.; Naymagon, L.; Tremblay, D.; Chokshi, K.; Dua, S.; Dunn, A.; Powell, C.; Bose, S. title: Cardiovascular disease and severe hypoxemia associated with higher rates of non-invasive respiratory support failure in COVID-19 date: 2020-09-29 journal: nan DOI: 10.1101/2020.09.27.20202747 sha: dbd0d3d1251dc36000c25b18bf7c0707b4f77c3d doc_id: 901600 cord_uid: 5qt588r5 Rationale Acute hypoxemic respiratory failure (AHRF) is the major complication of coronavirus disease 2019 (COVID-19), yet optimal respiratory support strategies are uncertain. Objectives To describe outcomes with high-flow oxygen delivered through nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) in COVID-19 AHRF and identify individual factors associated with failure. Methods We performed a retrospective cohort study of hospitalized adults with COVID-19 treated with HFNC and/or NIPPV to describe rates of success (live discharge without endotracheal intubation (ETI)), and identify characteristics associated with failure (ETI and/or in-hospital mortality) using Fine-Gray sub-distribution hazard models. Results A total of 331 and 747 patients received HFNC and NIPPV as the highest level of non-invasive respiratory support, respectively; 154 (46.5%) in the HFNC cohort and 167 (22.4%) in the NIPPV cohort were successfully discharged without requiring ETI. In adjusted models, significantly increased risk of HFNC and NIPPV failure was seen among patients with cardiovascular disease (subdistribution hazard ratio (sHR) 1.82; 95% confidence interval (CI), 1.17-2.83 and sHR 1.40; 95% CI 1.06-1.84), respectively, and among those with lower oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at HFNC and NIPPV initiation (sHR, 0.32; 95% CI 0.19-0.54, and sHR 0.34; 95% CI 0.21-0.55, respectively). Conclusions A significant proportion of patients receiving non-invasive respiratory modalities for COVID-19 AHRF achieved successful discharge without requiring ETI, with lower success rates among those with cardiovascular disease or more severe hypoxia. The role of non-invasive respiratory modalities in COVID-19 related AHRF requires further consideration. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint A significant proportion of patients receiving non-invasive respiratory modalities for COVID-19 AHRF achieved successful discharge without 68 requiring ETI, with lower success rates among those with cardiovascular disease or more severe hypoxemia. The role of non-invasive respiratory 69 modalities in COVID-19 related AHRF requires further consideration. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic, 80 resulting in over 16.5 million cases and more than 655,000 deaths across 216 countries (1) . The burden of cases in the United States has 81 exceeded that of any other country, with New York City as the epicenter of the pandemic at the time of this study, accounting for over 226,000 82 cases as of July 30, 2020 (2). The hallmark of COVID-19 is the development of acute respiratory illness, with a significant number of hospitalized 83 adult patients progressing to acute respiratory distress syndrome (ARDS) (3-6), and up to 18% ultimately requiring endotracheal intubation (ETI) 84 and invasive mechanical ventilation (IMV) (5-9). Importantly, mortality rates after ETI are substantial, ranging from 65-96% (3, 4, 7, 10). While some experts during the pandemic have advocated for early ETI and invasive mechanical ventilation (IMV) (11), the optimal respiratory 87 support strategy for COVID-19 acute hypoxemic respiratory failure (AHRF) remains unclear (12). Compared to low-flow supplemental oxygen, HFNC improves oxygenation and work of breathing (13) and reduces ETI rates (14-16), while NIPPV may be associated with a lower risk of both 89 ETI and mortality in certain non-COVID-19 populations with AHRF (16). Despite these benefits, some studies have shown that treatment failure 90 with HFNC and NIPPV is associated with worse outcomes, including increased mortality, possibly related to delayed ETI and initiation of IMV (17-91 19). Reports of outcomes with HFNC and NIPPV in the COVID-19 population, however, remain limited to small case series (20, 21), with 92 significant variability in use of these modalities across centers (3, 9, 10, 22). Accordingly, individual characteristics associated with HFNC and 93 NIPPV failure in COVID-19 AHRF are unknown. Unclear benefits of HFNC and NIPPV have resulted in some experts advocating for avoidance of 94 these modalities in favor of early ETI during the pandemic (23). All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint To address this knowledge gap, we sought to describe patterns of HFNC and NIPPV use and outcomes for patients admitted with COVID-19 AHRF 97 within a large New York City academic health system. We subsequently identified specific demographic and clinical characteristics at the time of 98 HFNC and NIPPV initiation that were associated with HFNC and NIPPV failure, highlighting patient subgroups particularly susceptible to poor 99 outcomes with non-invasive respiratory support. For the descriptive study aim, we included all hospitalized patients between >18 and 100 years of admitted between March 1 and April 28, 2020 109 with a positive SARS-CoV-2 reverse transcriptase polymerase chain reaction of nasopharyngeal swab samples, and who required HFNC and/or 110 NIPPV prior to achieving an outcome of first ETI, live hospital discharge, or in-hospital mortality ( Figure 1 ). Patients were followed up to May 31, 111 2020. Patients from the descriptive population without missing covariates were included in the analytic subset ( Figure 1 ). For transferred 112 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint patients, defined as discharged from one of five hospital sites with readmission at another within 12 hours, both admissions were included as a 113 single hospitalization. If a patient was discharged for a period of >12 consecutive hours and subsequently readmitted, only the first admission 114 was considered. Data were extracted from electronic databases, including Epic Clarity and Epic Caboodle (Epic Systems Corporation). ETI timings for 400 patients 117 were validated using chart review; only 3 out of 400 (0.75%) showed inconsistencies with the automatically extracted data due to charting 118 errors. Data collected included hospital disposition (either live discharge or death), patient demographics, code status of do-not-intubate (DNI), 119 comorbidities (captured using ICD-10 codes), medications (including anticoagulation therapies and corticosteroids), vital signs, laboratory tests, 120 and treatment with respiratory support devices (nasal cannula, face mask, non-rebreather mask, HFNC, NIPPV (defined as continuous or bilevel 121 positive pressure devices), and/or ETI with IMV). The last recorded vital signs and laboratory values prior to device initiation were selected; if 122 these were not available (for example, if the patient was placed on a device immediately at the time of admission) the measurements occurring 123 soonest after device initiation were selected. The primary outcome was treatment success, defined as live hospital discharge without need for ETI. Treatment failure was defined as ETI 127 and/or in-hospital mortality, whichever occurred first, to account for patients who may have died before ETI documentation (e.g. during 128 cardiopulmonary resuscitation), or for whom IMV may have been indicated but who died without ETI due to DNI code status. Secondarily, in 129 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint multivariable models including the subset of patients with non-missing data for covariates included in the main model, we explored specific 130 demographic and clinical characteristics at the time of HFNC or NIPPV initiation that were associated with treatment failure. Non-invasive respiratory support cohorts To simplify multiple transitions between HFNC and NIPPV that often take place during hospitalization, each patient was categorized into one of 134 two cohorts based on the highest level of non-invasive respiratory support required prior to outcome (as defined above), or if no outcome was 135 observed, the end of the study period. Accordingly, the HFNC cohort included patients who received HFNC but never NIPPV, while the NIPPV 136 cohort included patients who received NIPPV, or both HFNC and NIPPV at any point between hospital admission and outcome, irrespective of 137 sequence. In addition, timing of initiation and total duration of HFNC and/or NIPPV use from hospital admission to an outcome were calculated. Patient demographics included age, sex, race/ethnicity, and insurance type, as well as hospital site. Clinical factors included comorbidities, 141 smoking status, body mass index (BMI), and DNI code status (if documented prior to HFNC or NIPPV initiation), as well as vital signs, ratio of 142 peripheral blood oxygen saturation to fraction of inspired oxygen (SpO 2 /FiO 2 ), and laboratory tests at the time of HFNC or NIPPV initiation. Enrollment into investigational drug trials for COVID-19 was not included as a covariate, as only a portion of those enrolled ultimately received 144 the investigational agent and data regarding specific therapies could not be reported due to embargo. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. Covariates in the univariable models with p≤0.15 were entered into multivariable models for each cohort (Table E1 ). All continuous variables 153 used in models, except for age and temperature, were natural-log transformed to address observed skew in their underlying distributions (a 154 standard procedure in regression models). We performed the following sensitivity analyses to test the robustness of the outcomes from the main model: (1) Addition of prophylactic-and 157 therapeutic-dose anticoagulation and/or corticosteroids administered prior to device initiation as individual covariates in the multivariable 158 models, as these interventions may have impacted the risk of failure and clinical characteristics may also differ by treatment status; (2) excluding 159 interleukin-6 and BMI, the two covariates with the most missing values, from the multivariable models to increase sample size and better 160 represent the initial study population; and (3) evaluating differences in demographics and clinical characteristics between patients with and 161 without any missing covariates (irrespective of whether they were included in adjusted models). P-values <0.05 were considered statistically 162 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint significant. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC), and R (Version 3.5.0) using Rstudio (Version 1. Considering dynamic respiratory support requirements including room air and low flow supplemental oxygen over time for a given patient, the 178 highest time-varying probability of receiving HFNC was 36% among those in the HFNC cohort, occurring between days 5-6 of admission ( Figure 179 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint 2). Among patients in the NIPPV cohort, the highest time-varying probability of being on NIPPV (31%) occurred within the first day of admission, 180 while HFNC use in the same group was 12% on day 5 of admission ( Figure 2 ). Outcomes in the HFNC cohort Out of 331 patients in the HFNC cohort, 154 (46.5%) were successfully discharged without needing ETI during their hospital stay ( Figure 3A ). Of 184 the 177 (53.5%) who experienced HFNC failure, 100 (56.5%) required ETI and 77 (43.5%) died without ETI. Among the 100 patients who 185 ultimately required ETI, 35 (35.0%) were eventually discharged, 58 (58.0%) died and 7 (7.0%) were censored ( Figure 3A ). The median (IQR) 186 follow-up time in the overall HFNC cohort from time to device initiation to any of the defined outcomes (failure, success, or the end of study for 187 those who did not experienced failure or successful discharge) was 5.40 (1.00, 10.7) days, and specifically, was 1.36 (0.54, 3.77) days and 10.2 188 (6.72, 15.5) days among those who experienced treatment failure and successful discharge, respectively. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. Figure 3B ). The median (IQR) follow-up time for the NIPPV cohort was 4.1 (1.2, 9.1) days, and 201 specifically, was 2.6 (0.8, 6.7) days and 11.2 (6.8, 17.6) days for those with treatment failure and success, respectively. Factors associated with NIPPV failure In multivariable analysis limited to the subset of patients in the NIPPV cohort with complete data for all adjusted covariates (n = 408), co-morbid 205 cardiovascular disease and higher interleukin-6 were associated with increased risk of failure (sHR 1.40; 95% CI, 1.07-1.84, and sHR 1.13; 95% CI In sensitivity analyses where receipt of prophylactic or therapeutic anticoagulation and/or corticosteroids prior to device initiation were added 211 as covariates, co-morbid cardiovascular disease and lower SpO 2 /FiO 2 ratio remained significantly associated with increased risk of failure in both 212 HFNC (Table E3 ) and NIPPV cohorts (Table E4) . Similarly, despite differences in demographic and clinical characteristics between patients with 213 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint overall complete vs. incomplete covariate data (Table E5 ), significant associations between cardiovascular disease and SpO 2 /FiO 2 ratio remained 214 in models where interleukin-6 and BMI were excluded to encompass a larger subset of patients (Tables E3 and E4 ). This is the largest cohort study in patients with COVID-19 AHRF to date to describe patterns of use and outcomes with non-invasive respiratory 218 support modalities of HFNC and NIPPV. We observed that nearly half of the patients treated with HFNC and one-fifth of the patients treated with 219 NIPPV were successfully discharged without requiring ETI. As outcomes with HFNC and NIPPV were variable, we subsequently identified specific 220 clinical features, e.g. co-morbid cardiovascular disease, associated with increased risk of treatment failure (need for ETI and/or in-hospital 221 mortality). Recognition of these characteristics may help to identify vulnerable patient subgroups at higher risk of failure with non-invasive 222 modalities, thus necessitating closer monitoring. Similarly, more severe hypoxemia was associated with a higher rate of treatment failure in 223 those receiving non-invasive strategies, supporting their consideration primarily in patients with milder disease. Dedicated studies to evaluate 224 the efficacy of non-invasive modalities to reduce risks of ETI and mortality in COVID-19 AHRF are clearly warranted. Limited studies of non-invasive respiratory support outcomes in COVID-19 patients report survival rates of 19.5% to 100% with HFNC (4, 20, 21) 227 and 7.7% to 37.7% with NIPPV (3, 4). Although our aim was not to directly compare these non-invasive modalities, we found that a lower 228 proportion of patients receiving NIPPV were successfully discharged compared to HFNC. A higher failure rate among patients receiving NIPPV 229 may be due to higher illness severity or inherent differences in physiologic mechanisms of HFNC and NIPPV for AHRF (24). Specifically, NIPPV 230 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint use in non-COVID-19 severe ARDS patients has been shown to result in higher ICU mortality (19), which is potentially attributable to the self-231 inflicted lung injury phenomenon of high spontaneous respiratory drive, generation of large tidal volumes, and heterogeneity of ventilation and 232 regional distribution ventilation resulting in uncontrolled, potentially injurious transpulmonary pressures (25). Historically, treatment with NIPPV 233 for H1N1 influenza and the Middle East Respiratory Syndrome-coronavirus resulted in high failure rates leading to ETI, and clear benefits of 234 NIPPV use in SARS-CoV-1 have not been established (26). While we observed that a small subset of patients experienced good outcomes with 235 NIPPV, further studies comparing NIPPV with other forms of respiratory support are needed. Importantly, our observation that a subset of 236 patients using non-invasive respiratory support was successfully discharged from hospital without requiring ETI suggests that a uniform 237 approach of early ETI for all patients with COVID-19 AHRF deserves consideration (27-30). Avoidance of unnecessary ETI and IMV is paramount 238 to reduce IMV-associated complications, limit healthcare worker exposure associated with the ETI process (31), and preserve mechanical 239 ventilators in resource-constrained pandemic settings. Thus, the impact of non-invasive respiratory support modalities on reducing risk for ETI 240 and IMV and mortality merits further investigation. Closer examination of non-invasive respiratory support use patterns revealed that the highest probabilities of requiring HFNC or NIPPV occurred 243 relatively early in the hospital course, consistent with other studies reporting deteriorating respiratory status and development of ARDS soon 244 after admission (4, 5, 32). Notably, we found that the median time to treatment failure was within two days after initiation of HFNC or NIPPV, 245 highlighting that the immediate period after initiation of non-invasive respiratory support represents a crucial window for clinical deterioration 246 and progression of disease. This is consistent with non-COVID-19 studies which have demonstrated that, for example, a ROX index (ratio of 247 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint oxygen saturation/FiO 2 to respiratory rate) (33), of ≥4.88 after 12 hours of HFNC treatment for AHRF, is associated with a significantly lower 248 likelihood of requiring ETI (33). Furthermore, analysis of a subset of patients with non-COVID-19 ARDS treated with NIPPV from a large, 249 multicenter observational study showed that higher severity of illness, and worse oxygenation and ventilation over the first two days of NIPPV 250 use, were independently associated with the need for ETI (19, 34). Thus, in keeping with recommendations from the Surviving Sepsis Campaign 251 guidelines for COVID-19 (12), close monitoring and frequent reassessment of patients receiving non-invasive respiratory support, particularly 252 immediately after initiation, is essential. Notably, we found that comorbid cardiovascular disease, including ischemic heart disease, congestive heart failure, and arrhythmias, was 255 independently and robustly associated with increased risk of both HFNC and NIPPV failure. This finding is consistent with and expands upon 256 other observational studies, which have demonstrated that cardiovascular disease is a common comorbidity among COVID-19 patients treated 257 with non-invasive respiratory support and is associated with poor outcomes (35). This relationship has been hypothesized to stem from viral-258 mediated cardiac complications, including myocarditis, vascular inflammation with resultant cardiac injury and dysfunction, and new or 259 worsening cardiac arrhythmias (4, 36-39). Our work further highlights patients with cardiovascular disease as a vulnerable subgroup that is 260 susceptible to worse outcomes once initiated on non-invasive respiratory support. We also observed other important clinical characteristics associated with HFNC and NIPPV outcomes. As expected, patients with higher severity 263 of illness--as represented by more severe hypoxemia at non-invasive respiratory support initiation--were at significantly higher risk of both HFNC 264 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint and NIPPV failure. Further characterization of the mechanisms and the extent to which the distribution of gas exchange and regional ventilation 265 can be corrected by non-invasive therapies are needed to better predict disease trajectory and outcomes specific to COVID-19. Additionally, 266 laboratory markers suggestive of more severe immune dysregulation, specifically elevated interleukin-6 and lymphopenia, were independently 267 associated with failure in the NIPPV cohort. Interleukin-6 is a pro-inflammatory cytokine frequently upregulated in patients with severe COVID- Our study has notable strengths. First, this is the largest longitudinal cohort study to date to evaluate outcomes in patients treated with HFNC 278 and NIPPV on COVID-19 AHRF. Second, the granularity of our data enabled capture of accurate longitudinal data representing time-varying 279 laboratory results, vital signs and oxygenation status, and allowed us to map outcome trajectories associated with these devices. Third, the 280 diversity of our cohort, drawn from hospital sites representing distinct communities, improves the generalizability of our findings to other 281 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint COVID-19 populations. Fourth, we explored potential bias with several sensitivity analyses, accounting for patients with missing data and the 282 impact of anticoagulation and corticosteroids on the main analysis. Finally, we had a minimal number of censored patients, improving the 283 reliability of our outcomes. This study also has several limitations. As an observational study, we cannot draw conclusions on the utility of HFNC and NIPPV compared to 286 low-flow supplemental oxygen. However, our study provides a strong basis for further efforts, including case-control studies and randomized 287 controlled trials to investigate the efficacy of non-invasive respiratory support in reducing risks of ETI and mortality. Additionally, we chose to 288 focus on factors at the time of HFNC or NIPPV initiation associated with treatment outcome and did not address the impact of subsequent 289 changes in clinical characteristics or treatments administered. We were also limited to using SpO 2 /FiO 2 ratios to approximate degree of 290 hypoxemia (43), for which accurate interpretation of severity may be limited as arterial blood gases were unavailable for most patients. Furthermore, we did not account for HFNC flow rates and NIPPV inspiratory/expiratory pressures, which may have influenced outcomes. Finally, 292 we did not assess healthcare worker infectious exposure risk, though prior studies of healthcare workers exposed to SARS-CoV 1 patients on 293 HFNC or NIPPV did not report significantly higher transmission risk (44, 45) and in a COVID-19 simulation study, the exhaled air dispersion during 294 well-fitted HFNC and CPAP use was limited (46). author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint A subset of patients treated with HFNC and/or NIPPV achieved hospital discharge without requiring ETI and IMV, suggesting that some patients 298 with COVID-19 AHRF can be managed effectively with these respiratory support modalities. Attention to specific demographic and early clinical 299 factors, such as co-morbid cardiovascular disease and severity of hypoxemia, may help inform use of non-invasive respiratory strategies, 300 allowing for a more personalized approach to the management of AHRF in pandemic settings. We would like to thank our colleague Dr. Emilia Bagiella for her statistical input on this manuscript. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint 307 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint 308 or in-hospital mortality. 309 † Includes patients who received NIPPV as the highest non-invasive respiratory support prior to outcome of first endotracheal intubation, live hospital discharge 310 or in-hospital mortality. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. White blood cell count (x10 3 /µL) 9.0 (6.7, 11.9) 9.8 (7.2, 13.4) Peripheral lymphocyte (%) 9.6 (6. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. Missing sample size in the HFNC cohort included 38 for SpO 2 /FiO 2 ratio, 41 for body mass index, 3 for peripheral lymphocyte percent, 16 for D-Dimer, 13 for C-331 reactive protein, 11 for ferritin, 72 for interleukin-6, and 21 for pro-calcitonin. Missing sample size in the NIPPV cohort included 52 for SpO 2 /FiO 2 ratio, 132 for body mass index, 5 for peripheral lymphocyte percent, 40 for D-Dimer, 35 for 333 C-reactive protein, 37 for ferritin, 232 for interleukin-6, and 82 for pro-calcitonin. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint in the HFNC cohort, highest probability of receiving HFNC over the duration of hospital stay was 36%, which occurred between days 5 and 6 of 343 admission, and probabilities of treatment success (live hospital discharge without requiring endotracheal intubation (ETI)), and failure (required 344 ETI and/or in-hospital mortality) were 47% and 54%, respectively. Among patients in the NIPPV cohort, highest probability of receiving NIPPV 345 over the duration of hospital stay was 31%, which occurred within the first day of admission, while the highest probability of receiving HFNC was 346 12% on day 5 of admission. Probabilities of treatment success and failure for patients in the NIPPV cohort were 22% and 77%, respectively. HFNC: High-flow oxygen delivered through nasal cannula; NIPPV: Non-invasive positive pressure ventilation. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not certified by peer review) is the this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.27.20202747 doi: medRxiv preprint Systolic blood pressure 125 Diastolic blood pressure 73 SpO 2 /FiO 2 ratio 98 World Health Organization. Coronavirus disease (COVID-19) pandemic Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in 485 Patients With Coronavirus Disease Clinical course and risk factors for mortality of adult inpatients with COVID-19 in 487 Wuhan, China: a retrospective cohort study Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-489 Infected Pneumonia in Wuhan, China Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 491 China Presenting Characteristics, Comorbidities, and 493 Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Clinical Characteristics of Covid-19 in New York City Epidemiology, clinical course, and outcomes of 497 critically ill adults with COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in 499 China: a single-centered, retrospective, observational study Consensus statement: Safe Airway Society principles of 501 airway management and tracheal intubation specific to the COVID-19 adult patient group Surviving Sepsis Campaign: Guidelines on the Management of 503 Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) Physiologic Effects of High-Flow Nasal Cannula in Acute 505 Hypoxemic Respiratory Failure High flow nasal cannula compared with conventional oxygen 507 therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis High-flow oxygen through nasal cannula in acute hypoxemic 510 respiratory failure Association of Noninvasive Oxygenation 512 Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-513 analysis Failure of high-flow nasal cannula therapy may delay intubation and 515 increase mortality Benefits and risks of success or failure of noninvasive ventilation Noninvasive Ventilation of Patients with Acute Respiratory 519 Distress Syndrome. Insights from the LUNG SAFE Study The experience of high-flow nasal cannula in hospitalized patients with 2019 novel 522 coronavirus-infected pneumonia in two hospitals of Chongqing High flow nasal cannula is a good treatment option for COVID-19 Baseline Characteristics and Outcomes of 1591 Patients 526 Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Ventilation Techniques and Risk for 528 Transmission of Coronavirus Disease, Including COVID-19 High-Flow Nasal Cannula Oxygen in Adults: An Evidence-based Assessment Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure Noninvasive mechanical ventilation in high-risk 534 pulmonary infections: a clinical review COVID-19 Related Acute Respiratory Distress Syndrome: Not so Atypical COVID-19 pneumonia: different respiratory treatments 538 for different phenotypes? COVID-19 Does Not Lead to a "Typical" Acute Respiratory 540 Distress Syndrome Identification of pathophysiological patterns for triage and 542 respiratory support in COVID-19. The Lancet Respiratory Medicine COVID-19 and Risks Posed to Personnel During Endotracheal Intubation The timeline and risk factors of clinical progression of COVID-19 in Shenzhen An Index Combining Respiratory Rate and Oxygenation to 548 Predict Outcome of Nasal High-Flow Therapy Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries COVID-19 and cardiovascular disease: from basic mechanisms to clinical 553 perspectives Characteristics and outcomes of patients hospitalized 555 for COVID-19 and cardiac disease in Northern Italy Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus 559 Disease 2019 (COVID-19) Potential Effects of Coronaviruses on the Cardiovascular System: A Review. 561 COVID-19: immunopathogenesis and Immunotherapeutics Elevated levels of IL-6 and CRP predict 565 the need for mechanical ventilation in COVID-19 Clinical Characteristics of Coronavirus Disease 2019 in China Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS Risk factors for SARS transmission from patients 571 requiring intubation: a multicentre investigation in Toronto Transmission of severe acute respiratory syndrome during 573 intubation and mechanical ventilation Exhaled air dispersion distances during noninvasive ventilation via different 575 Respironics face masks